Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

Abstract Background Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance...

Full description

Bibliographic Details
Main Authors: Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock, Gerald Falchook
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Experimental Hematology & Oncology
Subjects:
Dual EGFR blockade
Cetuximab, erlotinib and bevacizumab
Advanced solid tumors
Phase 1 dose escalation
Online Access:http://link.springer.com/article/10.1186/s40164-020-00159-1

Internet

http://link.springer.com/article/10.1186/s40164-020-00159-1

Similar Items